Medite Cancer Diagnostics, Inc. (MDIT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMedite Cancer Diagnostics, Inc. (MDIT) trades at $0.0001. Medite Cancer Diagnostics, Inc. develops, manufactures, and markets medical devices and consumables for cancer detection and diagnosis. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for MDIT: MDIT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Medite Cancer Diagnostics, Inc. (MDIT) Healthcare & Pipeline Overview
Medite Cancer Diagnostics, Inc. is a medical technology company focused on developing and marketing diagnostic solutions for cancerous and precancerous conditions. Its portfolio includes a range of instruments and consumables used in histology and cytology labs, serving a global market with direct sales and distributor partnerships.
What Is the Investment Thesis for MDIT?
Medite Cancer Diagnostics, Inc. operates in the medical instruments and supplies industry, focusing on cancer diagnostics. The company's negative profit margin of -65.5% and ROE of -73.7% indicate financial challenges. A debt-to-equity ratio of 94.00 suggests a reliance on debt financing. The company's high beta of 552.83 indicates extreme volatility relative to the market. Growth catalysts include expansion into new geographic markets and the introduction of innovative diagnostic products. However, the company's financial performance and OTC market listing present significant risks.
Based on FMP financials and quantitative analysis
MDIT Key Highlights
Market capitalization of $0.00B indicates a small company size.
- Negative profit margin of -65.5% reflects operational inefficiencies or high costs.
- Gross margin of 23.7% suggests potential for improvement in production and sales strategies.
- Debt-to-equity ratio of 94.00 indicates a significant reliance on debt financing.
- Beta of 552.83 indicates extremely high volatility compared to the overall market.
Who Are MDIT's Competitors?
MDIT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| GCTK GlucoTrack, Inc. | $1.11 | -8.26% | — | |
| LUCY Innovative Eyewear, Inc. | $0.89 | -0.21% | $5.62M | — |
| FEMY Femasys Inc. | $2.02 | -1.46% | $6.31M | — |
| RGNT Regentis Biomaterials Ltd. | $1.67 | -9.73% | $12.2M | 64 5-pillar |
| MLSS Milestone Scientific Inc. | $0.36 | -4.23% | $34.1M | — |
| NEPH Nephros, Inc. | $3.55 | -3.27% | $39.4M | 33 5-pillar |
| POCI Precision Optics Corporation, Inc. | $4.46 | 0.00% | $48.7M | 37 5-pillar |
| MBOT Microbot Medical Inc. | $1.07 | -7.76% | $52.9M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDIT's Key Strengths?
Specialized product portfolio in cancer diagnostics.
- Distribution network in key geographic markets.
- Development of innovative self-collection devices.
- Comprehensive range of instruments and consumables.
What Are MDIT's Weaknesses?
Negative profit margin and ROE.
- High debt-to-equity ratio.
- Listing on the OTC market.
- Limited market capitalization.
What Are the Key Risks for MDIT?
Negative return on equity (-98.9%) — the business is not currently generating profit on shareholder capital.
- Negative profit margin and ROE impacting financial stability.
- Increased competition from larger medical device companies.
- Technological obsolescence of existing product lines.
- High debt-to-equity ratio increasing financial risk.
- OTC market listing indicating higher investment risk.
What Threats Does MDIT Face?
- Intense competition in the medical instruments and supplies industry.
- Stringent regulatory requirements.
- Technological obsolescence.
- Economic downturns affecting healthcare spending.
What Are MDIT's Competitive Advantages?
- Proprietary technology in ultrasonic decalcification and tissue processing.
- Established relationships with distributors in key geographic markets.
- Specialized product portfolio focused on cancer diagnostics.
- Development of innovative self-collection devices.
What Does MDIT Do?
Medite Cancer Diagnostics, Inc., based in Orlando, Florida, is a medical technology company specializing in the development, manufacture, and marketing of molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions. The company's origins are not detailed in the provided data. However, it has evolved to offer a comprehensive suite of products catering to histology and cytology laboratories. Its product line includes the USE 33 ultrasonic decalcification instrument, TPC 15 Duo and Trio tissue processing instruments, TES 99 and TES Valida cooling units, and a range of microtomes (M530, A550, M380, and M630). Additionally, Medite offers automated staining systems like the TST44 and COT 20, as well as robotic coverslippers such as the RCM 9000, ACS 720, and TWISTER. The company also develops the SoftKit device for self-collection of samples for female genital tract health assessment. Medite Cancer Diagnostics sells its products through direct sales and distributors in the United States, China, Europe, and North Africa, serving hospitals, research institutions, and independent laboratories.
What Products and Services Does MDIT Offer?
- Develops molecular biomarkers for cancer detection.
- Manufactures medical devices for histology and cytology laboratories.
- Markets consumables used in cancer diagnostics.
- Offers ultrasonic decalcification instruments.
- Provides tissue processing instruments.
- Produces microtomes for tissue sectioning.
- Develops robotic staining and coverslipping systems.
- Creates self-collection devices for female genital tract health assessment.
How Does MDIT Make Money?
- Direct sales of medical devices and consumables to hospitals and research institutions.
- Distribution partnerships in the United States, China, Europe, and North Africa.
- Revenue generation through the sale of molecular biomarkers.
- Sales of diagnostic instruments for cancer detection and risk assessment.
What Industry Does MDIT Operate In?
Medite Cancer Diagnostics, Inc. operates within the medical instruments and supplies industry, a segment driven by technological advancements in diagnostics and increasing prevalence of cancer. The industry is characterized by intense competition and stringent regulatory requirements. Medite competes with larger, more established players, requiring it to differentiate through innovation and strategic partnerships. The global medical devices market is projected to reach $600 billion by 2026, presenting growth opportunities for companies with specialized offerings.
Who Are MDIT's Key Customers?
- Histology laboratories associated with hospitals.
- Cytology laboratories associated with hospitals.
- Research institutions involved in cancer research.
- Independent laboratories providing diagnostic services.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Medite Cancer Diagnostics, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Orlando, US. The company is led by CEO Rahsan-Rahsan Lindsay. MDIT has traded publicly since 1995.
Key Financial Metrics
Return on equity for Medite Cancer Diagnostics, Inc. stands at -98.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -42.7%, showing how much profit it generates from its asset base. A current ratio of 0.92 means current liabilities exceed short-term assets, a liquidity point worth watching.
Insider Activity
12 transactions · 11 purchases, 0 sales, 1 other transactions · 4 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
MDIT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
MDIT Latest News
No recent news available for MDIT.
MDIT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MDIT.
Price Targets
Wall Street price target analysis for MDIT.
MDIT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MDIT; grades run from A+ (80-100) to F (below 30).
MDIT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing companies that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and may not be required to adhere to strict disclosure guidelines. This lack of transparency can increase the risk associated with investing in these companies compared to those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher potential for fraud or manipulation due to less regulatory oversight.
- Increased risk of delisting or company failure.
- Difficulty in obtaining accurate and timely information.
- Verify the company's registration and legal standing.
- Review available financial statements and assess their accuracy.
- Research the background and experience of the company's management team.
- Evaluate the company's business model and competitive landscape.
- Assess the company's compliance with regulatory requirements.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation for several years.
- Products are used in hospitals and research institutions.
- Presence of a distribution network in multiple countries.
- Development of innovative medical devices.
- Focus on cancer diagnostics, a critical area of healthcare.
MDIT Healthcare Stock FAQ
What do analysts say about MDIT stock?
As of March 16, 2026, there is no available analyst coverage or consensus for Medite Cancer Diagnostics, Inc. due to its listing on the OTC Other market and limited market capitalization.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited or delayed.